Human leukocyte antigen B27 and B51 double-positive Behçet uveitis

Archives of Ophthalmology

Volumn 125, Issue 10, 2007, Pages 1375-1380

  Jae, Kyoun Ahn ^a   Yeoung, Geol Park ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; HLA B27 ANTIGEN; HLA B51 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; STEROID;

ADULT; BEHCET DISEASE; CATARACT; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GENE EXPRESSION; GLAUCOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; OPTIC NERVE ATROPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RETINA DETACHMENT; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; REVIEW; SEX DIFFERENCE; UVEITIS; VISION; VITRECTOMY;

ADULT; BEHCET SYNDROME; FEMALE; GLUCOCORTICOIDS; HISTOCOMPATIBILITY TESTING; HLA-B ANTIGENS; HLA-B27 ANTIGEN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; UVEITIS;

EID: 35349029307     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.125.10.1375     Document Type: Review

References (25)

1. Ohno S, Ohguchi M, Hirose S, et al. Close association of HLA-Bw51 with Behçet's disease. Arch Ophthalmol. 1982;100(9):1455-1458.
2. Yazici H, Tuzun Y, Pazarli H, et al. The combined use of HLA-B5 and the pathergy test as diagnostic markers of Behçet's disease in Turkey. J Rheumatol. 1980;7(2):206-210.
3. Verity DH, Wallace GR, Vaughan RW, Standford MR. Behçet's disease: from Hippocrates to the third millennium. Br J Ophthalmol. 2003;87(9):1175-1183.
4. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Altunbas HH, Urgancioglu M. Uveitis in Behçet's disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373-380.
5. Ramsay A, Lightman S. Hypopyon uveitis. Surv Ophthalmol. 2001;46(1):1-18.
6. Takeuchi M, Hokama H, Tsukahara R, et al. Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement. Graefes Arch Clin Exp Ophthalmol. 2005;243:1147-1152 (11).
7. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet. 1990;335(8697):1078-1080.
8. Dougados M, van der Linden SJEF, Juhlin R, et al. The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum. 1991;34(10):1218-1227.
9. Lee DA, Barker SM, Daniel Su WP, et al. The clinical diagnosis of Reiter's syndrome: ophthalmic and nonophthalmic aspects. Ophthalmology. 1986;93(3):350-356.
10. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509-516.
11. Frauendorf E, vonGoessel H, May E, Marker-Hermann E. HLA-B27-restricted T cells from patients with ankylosing spondylitis recognize peptides from B*2705 that are similar to bacteria-derived peptides. Clin Exp Immunol. 2003;134(2):351-359.
12. Yasuoka H, Okazaki Y, Kawakami Y, et al. Autoreactive CD8+ cytotoxic T lymphocytes to major histocompatibility complex class I chain-related gene A in patients with Behçet's disease. Arthritis Rheum. 2004;50(11):3658-3662.
13. Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR. Behçet's disease, the silk road and HLA-B51: historical and geographical perspectives. Tissue Antigens. 1999;54(3):213-220.
14. Mizuki N, Ota M, Yabuki K, et al. Localization of the pathogenic gene of Behçet's disease by microsatellite analysis of three different populations. Invest Ophthalmol Vis Sci. 2000;41(12):3702-3708.
15. Chang HK, Kim SY. Survey and validation of the criteria for Behçet's disease recently used in Korea: a suggestion for modification of the International Study Group Criteria. J Korean Med Sci. 2003;18(1):88-92.
16. Gul A, Yyar A, Inanc M, et al. Lack of association of HLA-B51 with a severe disease course in Behçet's disease. Rheumatology (Oxford). 2001;40(6):668-672.
17. Demiroglu H, Barista I, Dundar S. Risk factor assessment and prognosis of eye involvement in Behçet's disease in Turkey. Ophthalmology. 1997;104(4):701-705.
18. Power WJ, Pedroza-Seres M, Foster CS. Outcomes in anterior uveitis associated with the HLA-B27 haplotype. Ophthalmology. 1998;105(9):1646-1651.
19. Ambresin A, Tao Tran V, Spertini F, Herbort CP. Behçet's disease in western Switzerland: epidemiology and analysis of ocular involvement. Ocul Immunol Inflamm. 2002;10(1):53-63.
20. Muhaya M, Lightman S, Ikeda E, et al. Behçet's disease in Japan and in Great Britain: a comparative study. Ocul Immunol Inflamm. 2000;8(3):141-148.
21. Linssen A, Meenken C. Outcomes of HLA-B27-positive and HLA-B27-negative acute anterior uveitis. Am J Ophthalmol. 1995;120(3):351-361.
22. Wakefield D, Montanaro A, McCluskey P. Acute anterior uveitis and HLA-B27. Surv Ophthalmol. 1991;36(3):223-232.
23. Ahn JK, Chung H, Lee DS, Yu YS, Yu HG. CD8brightCD56+ T cells are cytotoxic effectors in patients with active Behçet's uveitis. J Immunol. 2005;175(9):6133-6142.
24. Ahn JK, Yu HG, Chung H, Park YG. Intraocular cytokine environment in active Behçet uveitis. Am J Ophthalmol. 2006;142(3):429-434.
25. Ahn JK, Chung H, Yu HG. Vitrectomy for persistent panuveitis in Behçet's disease. Ocul Immunol Inflamm. 2005;13(6):447-453.